Jan 16, 2015
Once-daily oral medication to be reimbursed for first-line use
MISSISSAUGA, ON, Jan. 16, 2015 /CNW/ – Genzyme, a Sanofi company, announced today that the Manitoba Drug Program has included AUBAGIO™ (teriflunomide) 14 mg on the provincial drug formulary as a first-line oral agent for people in the province living with relapsing remitting multiple sclerosis (RRMS).
AUBAGIO is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
“The prompt inclusion of an additional therapy onto the Manitoba Drug Benefits Formulary is an issue of fundamental importance to Manitobans affected by MS,” states Donna Boyd, President of the MS Society, Manitoba Division. “Now that an additional therapy is covered under the Manitoba Pharmacare Program, persons with MS and their physicians have the option to choose a first-line, orally administered drug therapy that has been shown to be safe and effective. The MS Society thanks the Government of Manitoba for moving so swiftly to make this new therapy available.”
About MS in CanadaWith 100,000 Canadians living with MS and three people newly diagnosed every day, Canada has one of the highest prevalence rates in the world. As most people are diagnosed with relapsing MS in their twenties and thirties, MS is the most common neurological disease affecting young adults in Canada.
“We applaud the Government of Manitoba for ensuring that AUBAGIO is available to patients suffering from RRMS. With its once-a-day oral regimen, this will provide patients an alternative to injectables,” said Peter Brenders, General Manager, Genzyme Canada.
As part of its commitment to those living with MS, Genzyme has developed the MS One to One™ program which offers comprehensive information services and ongoing education as well as reimbursement navigation. Staffed by dedicated MS nurses and highly trained representatives, MS One to One provides support for individuals living with MS, their healthcare providers, family and loved ones.
About AUBAGIO™ (Teriflunomide)
Click here to continue reading
~~~~~~~~~~~~~~~~~~~~
.
.
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
